Medigrowth Australia has appointed Dr Ashleigh Osborne, a former Canopy Growth manager, as its national medical lead.
Osborne spent four and a half years at Canopy Growth, where she began as a medical science liaison in NSW in April 2020 and advanced to the role of country medical affairs manager in October 2022.
Medigrowth chief executive Adam Guskich said Osborne would bring a "passion" for cannabinoid-based medicine to the company, and described her work in destigmatising medicinal cannabis through scientific communication as "truly inspiring".
He added Osborne's expertise in regulatory affairs, clinical research and multiple therapeutic areas would be "invaluable" to Medigrowth.
The People’s Plant
A surge of last-minute contributions to a Birchal crowdsource funding campaign pushed The People's Plant just beyond the A$1 million threshold.
The Sunshine Coast-based cultivator had collected $770,000 from 400 investors on the morning of the campaign's final day, but ultimately closed with $1,031,585 from 641 investors.
The company had set a minimum fundraising goal of $250,000 and a maximum of $2m.
Co-founder Rebecca Risby-Jones said she was "thrilled" by the response.
Epsilon Healthcare
The Deed of Company Arrangement (DOCA) covering Epsilon Pharma and Epsilon Clinics has now been executed, though management continues to "address matters" concerning the parent entity, Epsilon Healthcare, the company has confirmed.
The DOCA was proposed in June by deputy chairman Alan Beasley and chief executive Peter Giannopoulos — and approved by creditors — following a seven-month period in voluntary administration.
In an ASX update, Epsilon noted that while the subsidiary DOCA has been wrapped up, outstanding work remains at the Epsilon Healthcare level. The company did not disclose what specific issues still need to be resolved.
"[We] will advise about specific outcomes and next steps in due course," the company said. "The Epsilon board would like to sincerely thank clients and supply partners for their patience and support during the regrettable period of voluntary administration.
"With the completion of the DOCA, the management and board can now refocus on supporting its people to deliver exceptional services and care to clients and patients."
Byron Bay Bio
Byron Bay Bio has secured A$233,168 from 122 investors with one day still remaining in its Birchal crowdsource funding campaign.
The technology and product supplier set a maximum target of $1.5m, with plans that include a move to patent seeds via DNA genome sequencing and the registration of an over-the-counter CBD muscle balm.
